As shown in Figures 2(A) and S3(A), in addition to being expressed in CD8+ T (23–33%) and NK cells (11.5–21%), NKG2A was also expressed in other PBMCs (41–69%), suggesting that the intravenously administrated NKG2A-targeted IL-2Rβγ agonist might be predominantly captured by these cells in blood, which might reduce the tumor uptake of the NKG2A-targeted IL-2Rβγ agonist. This evidence concerns the gene CD8A and neoplasm.